Cargando…

Prevalence of cryptococcal antigenuria at initial HIV diagnosis in KwaZulu‐Natal

OBJECTIVES: The World Health Organization (WHO) recommends screening HIV‐infected people for cryptococcal antigens to identify cryptococcosis, a major cause of AIDS‐related deaths. As the burden of cryptococcosis is unknown in South Africa's KwaZulu‐Natal province, we assessed the cryptococcal...

Descripción completa

Detalles Bibliográficos
Autores principales: Drain, PK, Kleene, JM, Coleman, SM, Losina, E, Katz, JN, Giddy, J, Ross, D, Freedberg, KA, Bassett, IV
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4618243/
https://www.ncbi.nlm.nih.gov/pubmed/25958770
http://dx.doi.org/10.1111/hiv.12263
_version_ 1782396900248387584
author Drain, PK
Kleene, JM
Coleman, SM
Losina, E
Katz, JN
Giddy, J
Ross, D
Freedberg, KA
Bassett, IV
author_facet Drain, PK
Kleene, JM
Coleman, SM
Losina, E
Katz, JN
Giddy, J
Ross, D
Freedberg, KA
Bassett, IV
author_sort Drain, PK
collection PubMed
description OBJECTIVES: The World Health Organization (WHO) recommends screening HIV‐infected people for cryptococcal antigens to identify cryptococcosis, a major cause of AIDS‐related deaths. As the burden of cryptococcosis is unknown in South Africa's KwaZulu‐Natal province, we assessed the cryptococcal antigenuria prevalence among newly diagnosed HIV‐infected adults there. METHODS: We conducted a cross‐sectional study of newly diagnosed HIV‐infected adults who received voluntary HIV testing in an out‐patient clinic. Participants provided a urine specimen in a sterile container, and we performed testing with a WHO‐endorsed rapid cryptococcal antigen lateral flow assay (Immy Inc., Norman, OK, USA) per the manufacturer's specifications. We assessed cryptococcal antigenuria prevalence among participants with CD4 counts < 200 cells/μL, and stratified results by CD4 count categories. RESULTS: Among 432 participants, the mean (± standard deviation) age was 36.1 ± 9.9 years and 172 (40%) were female. The overall estimated prevalence of cryptococcal antigenuria was 9.0% [95% confidence interval (CI) 6.5–12.1%]. CD4 counts were available for 319 participants (74%); the median CD4 count was 75 cells/μL [interquartile range (IQR) 34–129 cells/μL]. Participants with a negative cryptococcal antigenuria screening test had a median CD4 count of 79 cells/μL (IQR 36–129 cells/μL), while participants with a positive cryptococcal test had a median CD4 count of 41 cells/μL (IQR 10–112 cells/μL). The estimated prevalence of cryptococcal antigenuria among participants with CD4 counts < 50 cells/μL was 12.5% (95% CI 7.0–20.1%), which was significantly higher than that among participants with CD4 counts of 50–200 cells/μL (4.8%; 95% CI 2.3–8.7%). CONCLUSIONS: Nearly 1 in 10 newly diagnosed HIV‐infected adults with CD4 counts < 200 cells/μL in KwaZulu‐Natal had evidence of cryptococcal antigenuria. Point‐of‐care CD4 count testing and cryptococcal antigen screening may rapidly identify cryptococcosis at the time of HIV diagnosis.
format Online
Article
Text
id pubmed-4618243
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-46182432016-10-19 Prevalence of cryptococcal antigenuria at initial HIV diagnosis in KwaZulu‐Natal Drain, PK Kleene, JM Coleman, SM Losina, E Katz, JN Giddy, J Ross, D Freedberg, KA Bassett, IV HIV Med Short Communications OBJECTIVES: The World Health Organization (WHO) recommends screening HIV‐infected people for cryptococcal antigens to identify cryptococcosis, a major cause of AIDS‐related deaths. As the burden of cryptococcosis is unknown in South Africa's KwaZulu‐Natal province, we assessed the cryptococcal antigenuria prevalence among newly diagnosed HIV‐infected adults there. METHODS: We conducted a cross‐sectional study of newly diagnosed HIV‐infected adults who received voluntary HIV testing in an out‐patient clinic. Participants provided a urine specimen in a sterile container, and we performed testing with a WHO‐endorsed rapid cryptococcal antigen lateral flow assay (Immy Inc., Norman, OK, USA) per the manufacturer's specifications. We assessed cryptococcal antigenuria prevalence among participants with CD4 counts < 200 cells/μL, and stratified results by CD4 count categories. RESULTS: Among 432 participants, the mean (± standard deviation) age was 36.1 ± 9.9 years and 172 (40%) were female. The overall estimated prevalence of cryptococcal antigenuria was 9.0% [95% confidence interval (CI) 6.5–12.1%]. CD4 counts were available for 319 participants (74%); the median CD4 count was 75 cells/μL [interquartile range (IQR) 34–129 cells/μL]. Participants with a negative cryptococcal antigenuria screening test had a median CD4 count of 79 cells/μL (IQR 36–129 cells/μL), while participants with a positive cryptococcal test had a median CD4 count of 41 cells/μL (IQR 10–112 cells/μL). The estimated prevalence of cryptococcal antigenuria among participants with CD4 counts < 50 cells/μL was 12.5% (95% CI 7.0–20.1%), which was significantly higher than that among participants with CD4 counts of 50–200 cells/μL (4.8%; 95% CI 2.3–8.7%). CONCLUSIONS: Nearly 1 in 10 newly diagnosed HIV‐infected adults with CD4 counts < 200 cells/μL in KwaZulu‐Natal had evidence of cryptococcal antigenuria. Point‐of‐care CD4 count testing and cryptococcal antigen screening may rapidly identify cryptococcosis at the time of HIV diagnosis. John Wiley and Sons Inc. 2015-05-11 2015-11 /pmc/articles/PMC4618243/ /pubmed/25958770 http://dx.doi.org/10.1111/hiv.12263 Text en © 2015 The Authors. HIV Medicine published by John Wiley & Sons Ltd on behalf of British HIV Association This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial‐NoDerivs (http://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Short Communications
Drain, PK
Kleene, JM
Coleman, SM
Losina, E
Katz, JN
Giddy, J
Ross, D
Freedberg, KA
Bassett, IV
Prevalence of cryptococcal antigenuria at initial HIV diagnosis in KwaZulu‐Natal
title Prevalence of cryptococcal antigenuria at initial HIV diagnosis in KwaZulu‐Natal
title_full Prevalence of cryptococcal antigenuria at initial HIV diagnosis in KwaZulu‐Natal
title_fullStr Prevalence of cryptococcal antigenuria at initial HIV diagnosis in KwaZulu‐Natal
title_full_unstemmed Prevalence of cryptococcal antigenuria at initial HIV diagnosis in KwaZulu‐Natal
title_short Prevalence of cryptococcal antigenuria at initial HIV diagnosis in KwaZulu‐Natal
title_sort prevalence of cryptococcal antigenuria at initial hiv diagnosis in kwazulu‐natal
topic Short Communications
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4618243/
https://www.ncbi.nlm.nih.gov/pubmed/25958770
http://dx.doi.org/10.1111/hiv.12263
work_keys_str_mv AT drainpk prevalenceofcryptococcalantigenuriaatinitialhivdiagnosisinkwazulunatal
AT kleenejm prevalenceofcryptococcalantigenuriaatinitialhivdiagnosisinkwazulunatal
AT colemansm prevalenceofcryptococcalantigenuriaatinitialhivdiagnosisinkwazulunatal
AT losinae prevalenceofcryptococcalantigenuriaatinitialhivdiagnosisinkwazulunatal
AT katzjn prevalenceofcryptococcalantigenuriaatinitialhivdiagnosisinkwazulunatal
AT giddyj prevalenceofcryptococcalantigenuriaatinitialhivdiagnosisinkwazulunatal
AT rossd prevalenceofcryptococcalantigenuriaatinitialhivdiagnosisinkwazulunatal
AT freedbergka prevalenceofcryptococcalantigenuriaatinitialhivdiagnosisinkwazulunatal
AT bassettiv prevalenceofcryptococcalantigenuriaatinitialhivdiagnosisinkwazulunatal